admin

CBT Pharmaceuticals Presents Data Demonstrating Anti-Tumor Activity of its Highly Specific c-MET Inhibitor, Bozitinib (CBT-101), at AACR Annual Meeting 2017 Data demonstrates anti-tumor activity in gastric, hepatic, lung and pancreatic cancer models A Phase 1 study of bozitinib in patients with select advanced relapsed/recurrent c-MET dysregulated solid tumors to be initiated in 2017  Santa Clara, […]

CBT Pharmaceuticals (Australia) Pty Ltd Established Santa Clara, CA – March 30, 2017 – CBT Pharmaceuticals, Inc. (CBT), a life sciences company focused on developing innovative oncology therapeutics, announced today that the first patient has been enrolled in the genolimzumab (CBT-501) Phase 1 study, the company’s first clinical trial. The trial is designed to evaluate

Data demonstrates comparable or improved anti-tumor activity over marketed PD-1 antibody in preclinical model of colon cancer A Phase 1 study of genolimzumab (CBT-501) in patients with select advanced relapsed/recurrent solid tumors to be initiated in 1H 2017 Santa Clara, CA – February 23, 2017 – CBT Pharmaceuticals, Inc. (CBT), a life sciences company focused

CBT Pharmaceuticals Closes $9.75 Million Series A Financing Led by OrbiMed for Development of Oncology Pipeline –$14.75 million total capital raised will advance targeted medicine and immune-oncology programs into the clinic –Gavin Choy, PharmD, MBA, appointed Executive Vice-President and Chief Operating Officer Santa Clara, CA, Aug. 29, 2016 — CBT Pharmaceuticals (CBT), a life sciences